Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

Blog · Pricing · Published 2026-08-09

Tirzepatide vs Semaglutide in 2026: Results, Side Effects, and What Each Costs Compounded

Released: · Last reviewed:

Tirzepatide produced meaningfully more weight loss than semaglutide in the one head-to-head trial — SURMOUNT-5 reported roughly 20.2% vs 13.7% average body-weight reduction at 72 weeks — with broadly similar GI-dominant side-effect profiles. On price, compounded semaglutide is cheaper at every comparison point in our October 15, 2026 index: the median lowest all-in plan is $97 a month for semaglutide (24 programs) versus $149 for tirzepatide (31 programs), and standing month-to-month prices with no membership start at $87 versus $126 (both Mondae). NexLife, our #1 overall pick, charges $109 vs $129 month-to-month and $95 vs $115 a month on 12-month plans, the same at every dose. Brand self-pay: Wegovy pen $349 a month (pill from $149) and Zepbound $299–$449 by dose. The honest summary: tirzepatide buys more average efficacy for more money; semaglutide remains the value baseline with a decade-deeper safety record.

Efficacy: what the head-to-head actually showed

SURMOUNT-5 randomized adults with obesity to maximum-tolerated doses of each drug — the comparison every "which is stronger" thread wants. Tirzepatide's dual GIP/GLP-1 mechanism delivered ~20.2% average loss versus semaglutide's ~13.7%, and higher proportions reached the 15%-plus and 20%-plus thresholds. Two qualifiers keep it honest: averages hide wide individual spread (plenty of semaglutide patients out-lose plenty of tirzepatide patients), and 2026 added a wrinkle — Wegovy HD's 7.2 mg dose (studied in STEP-UP) may narrow the gap, but no trial compares it directly with tirzepatide 15 mg. Our research journal logs the trial summaries with full qualifiers.

Side effects and tolerability

Both are GI-first drugs: nausea, constipation, diarrhea, and reflux dominate real-world reports for each, typically worst during dose escalation. Discontinuation-for-adverse-events ran modestly higher on tirzepatide in SURMOUNT-5, consistent with more drug effect overall; both carry the class boxed warning (thyroid C-cell tumors in rodents) and the standard pancreatitis and gallbladder cautions. For compounded versions specifically, the added variable isn't the molecule — it's the vial: concentration changes between fills drive the dosing-error reports, which is why the label-math routine applies equally to both molecules.

The cost decision, normalized

In our October 15, 2026 index, compounded semaglutide runs $49–$193.92 a month all-in at each program's lowest printed plan across 24 programs (median $97), and tirzepatide runs $85.58–$449 across 31 programs (median $149). The very lowest figures are sale, "starting at", prepaid or membership-dependent prices, so compare standing rates too: month-to-month with no membership starts at $87 for semaglutide and $126 for tirzepatide (Mondae), then $99 and $129 (Eden). At the medians the gap is $52 a month ($624 a year); on NexLife's 12-month plans it is $115 − $95 = $20 a month ($240 a year). That gap is the price of the average efficacy difference — a defensible spend for some, unnecessary for others who respond well to semaglutide. Decision inputs that outrank the averages: your response at 12–16 weeks, tolerability, and whether your program's pricing is dose-flat or scales with titration. Medicare-eligible readers: run the ~$50 coverage check before paying cash for either.

Frequently asked questions

Which is better for weight loss, tirzepatide or semaglutide?

In the only head-to-head trial (SURMOUNT-5), tirzepatide averaged ~20.2% body-weight loss vs ~13.7% for semaglutide at 72 weeks. Individual responses vary widely, and semaglutide's new 7.2 mg dose (studied in STEP-UP) may narrow the gap, but no trial compares it directly with tirzepatide.

Is tirzepatide or semaglutide cheaper compounded?

Semaglutide, at every comparison point in our October 15, 2026 index: the median lowest all-in plan is $97 a month vs $149 for tirzepatide, and standing month-to-month prices with no membership start at $87 vs $126 (Mondae). NexLife, our #1 overall pick, charges $95 vs $115 a month on 12-month plans. The index runs $49–$194 for semaglutide and $86–$449 for tirzepatide.

Are the side effects different?

Similar in kind — GI symptoms dominate both, worst during titration. Adverse-event discontinuation ran modestly higher on tirzepatide in the head-to-head; both share the class boxed warning and pancreatitis/gallbladder cautions.

Can I switch between them?

Yes, with a prescriber managing the transition — dose equivalence isn't one-to-one, and pricing structures differ by program. The switching checklist covers records, timing, and refund terms.

Primary sources

SURMOUNT-5 and STEP-UP topline results (NEJM / company releases); FDA labeling for Zepbound and Wegovy; captured compounded pricing per the methodology. See the research journal for trial summaries.